original articles
AnnalsofOncology
AnnalsofOncology24:75–83,2013
doi:10.1093/annonc/mds213
Publishedonline2August2012
Ipilimumab in combination with paclitaxel
fi
and carboplatin as rst-line therapy in extensive-
disease-small-cell lung cancer: results from a
†
randomized, double-blind, multicenter phase 2 trial
M. Reck1*, I. Bondarenko2, A. Luft3, P. Serwatowski4, F. Barlesi5, R. Chacko6, M. Sebastian7,
H. Lu8, J. -M. Cuillerot8 & T. J. Lynch9
1DepartmentofThoracicOncology,HospitalGrosshansdorf,Grosshansdorf,Germany;2ClinicalFacility,DnepropetrovskCityHospital,Dnepropetrovsk,Ukraine;
3LeningradRegionalClinicalHospital,St.Petersburg,Russia;4DepartmentofChemotherapy,SpecjalistycznySzpitalim.,Szczecin,Poland;5FacultyofMedicine,Service
d’OncologieMultidisciplinaire&InnovationsThérapeutiques,UniversityofMediterranée,AssistancePubliqueHopitauxdeMarseille,Marseille,France;6Departmentof
MedicalOncology,ChristianMedicalCollege,Vellore,India;7DepartmentofMedicineIII,MedicalCenteroftheJohannesGutenbergUniversitaetsmedizin,Mainz,
Germany;8ResearchandDevelopment,Bristol-MyersSquibb,Wallingford;9YaleCancerCenterandSmilowCancerHospital,NewHaven,USA
Received1February2012;revised23May2012&30May2012;accepted31May2012
Background:Ipilimumab,ananti-CTLA4monoclonalantibody,demonstratedsurvivalbenefitinmelanomawith
immune-related(ir)adverseevents(irAEs)managedbytheprotocol-definedguidelines.Thisphase2studyevaluated
ipilimumab+paclitaxel(Taxol)/carboplatininextensive-disease-small-celllungcancer(ED-SCLC).
Design:Patients(n=130)withchemotherapy-naïveED-SCLCwererandomized1:1:1toreceivepaclitaxel(175mg/
m2)/carboplatin(areaunderthecurve=6)witheitherplacebo(control)oripilimumab10mg/kgintwoalternative
regimens,concurrentipilimumab(ipilimumab+paclitaxel/carboplatinfollowedbyplacebo+paclitaxel/carboplatin)or
phasedipilimumab(placebo+paclitaxel/carboplatinfollowedbyipilimumab+paclitaxel/carboplatin).Treatmentwas
administeredevery3weeksforamaximumof18weeks(induction),followedbymaintenanceipilimumaborplacebo
every12weeks.Endpointsincludedprogression-freesurvival(PFS),irPFS,bestoverallresponserate(BORR);irBORR,
overallsurvival(OS),andsafety.
Results:Phasedipilimumab,butnotconcurrentipilimumab,improvedirPFSversuscontrol[HR(hazardratio)=0.64;
P=0.03].NoimprovementinPFS(HR=0.93;P=0.37)orOS(HR=0.75;P=0.13)occurred.Phasedipilimumab,
concurrentipilimumabandcontrol,respectively,wereassociatedwithmedianirPFSof6.4,5.7and5.3months;
medianPFSof5.2,3.9and5.2months;medianOSof12.9,9.1and 9.9months.Overallratesofgrade3/4irAEswere
17,21and 9%forphasedipilimumab,concurrentipilimumabandcontrol,respectively.
Conclusion:TheseresultssuggestfurtherinvestigationofipilimumabinED-SCLC.
Keywords:combinationtherapy,first-linetreatment,ipilimumab,paclitaxel/carboplatin,randomizedphase2trial,
small-celllungcancer
introduction withdifferentthirdgenerationcytotoxicagentsasfirst-line
treatmenthaveshownnoincrementalimprovementinOS
Combinationchemotherapiesarethecurrentstandardofcare
[1,3],underscoringtheneedfornoveltreatmentstrategies.
forextensive-disease-small-celllungcancer(ED-SCLC)[1,2].
CytotoxicT-lymphocyteantigen-4(CTLA-4),anegative
Despitehighinitialtumorresponsestothesetherapies,
regulatorofT-cellactivation,isananticancertargetofcurrent
recurrenceoccursrapidlywithmedianoverallsurvival(OS) interest [4–7].Ipilimumab,afullyhumananti-CTLA-4
rangingfrom8to11months[1,3].Phase3trialsoverthepast
monoclonalantibody,blockstheinteractionofCTLA-4with
30yearsevaluatingthecombinationsofcisplatinorcarboplatin
itsligands(CD80/CD86).ThisblockadeaugmentsT-cell
activationandproliferation,leadingtotumorinfiltrationbyT-
cellsandtumorregression[8–14].Earlyclinicaltrialswith
*Correspondenceto:DrM.Reck,DepartmentofPneumologyandThoracicSurgery,
ipilimumabhaveshowndurabletumorresponsesinmultiple
HospitalGrosshansdorf,Woehrendamm80,22927Grosshansdorf,Germany.
Tel:+49-4102-601188;Fax:+49-4102-691317;E-mail:dr.martin.reck@web.de cancertypes[15–18].Twophase3studieshavedemonstrated
ipilimumabasthefirstagenttosignificantlyimproveOSin
†Presentedinpartatthe14thWorldCongressonLungCancer,Amsterdam,The
Netherlands,3–7July2011(Recketal.Abstract#1365). patientswithmetastaticmelanoma[19,20].Adverseevents
©TheAuthor2012.PublishedbyOxfordUniversityPressonbehalfoftheEuropeanSocietyforMedicalOncology.
Allrightsreserved.Forpermissions,pleaseemail:journals.permissions@oup.com.
Downloaded
from
http://annonc.oxfordjournals.org/
at
St
Petersburg
State
University
on
December
6,
2013
original articles
AnnalsofOncology
(AEs)occurringin≥15%ofpatientsincludedpruritus,rash significantlyfromthosewith225mg/m2,with175mg/m2showingbetter
anddiarrhea,andmostAEsweremanagedbythedrug- safety[32].Patientswithoutprogressionwhocontinuedtotolerate
specifictreatmentguidelines[19,20]. treatmentreceivedeitheripilimumab(phased-andconcurrent-ipilimumab
SCLCpatientswithimmune-mediatedLambert-Eaton arms)orplacebo(controlarm)onceevery12weeksasmaintenanceuntil
myasthenicsyndromeappearedtostaylongerinlimited progression,deathorintolerance.
diseasestateandhaveimprovedsurvival[21].Long-term ThestudywasconductedinaccordancewiththeDeclarationof
survivorsofSCLCwerefoundtohaveahigherratioof Helsinki.Theprotocolwasapprovedbytheethicscommitteeateach
participatingcenter.Allpatientsprovidedwritteninformedconsentbefore
antitumoreffectorsTcellstoregulatoryTcellscomparedwith
enrollment(ClinicalTrials.govidentifier:NCT00527735).
thosewhohadrecurrentdisease[22].Theseobservations
suggestthatagentssuchasipilimumabthatactbypromoting
antitumorimmunitymaydelaytumorgrowthinpatientswith patients
SCLC.Thisrandomizedphase2studywasundertakento
ThisreportfocusesontheED-SCLCcohort.Eligiblepatientshad
evaluatetheactivityofipilimumabincombinationwith histologicallyorcytologicallyconfirmedED-SCLCwithbidimensionally
paclitaxel/carboplatinversuspaclitaxel/carboplatinalonein measurablelesions,were≥18yearsofage,receivednopriorsystemic
patientswithED-SCLC.Therationaleforcombining therapyforlungcancerandhadanEasternCooperativeOncologyGroup
ipilimumabwithchemotherapywasbasedonpreclinical performancestatusof0or1.Keyexclusioncriteriaincluded:prior
studiesshowingthatchemotherapeuticsinducethereleaseof treatmentwithCD137agonistorCTLA-4modulators;uncontrolled
tumor-specificantigensinitiatingT-cellactivationandsensitize
malignantpleuraleffusion;brainmetastases;priororcurrent
tumorcellstoT-cell-mediatedkilling[23–29],andthatcertain
paraneoplasticsyndromesrelatedtoSCLC;currentmalignanciesor
chemotherapeuticsenhancetheantitumoractivityofananti- previousmalignancieswithin5years;autoimmunedisease;≥grade
CTLA-4monoclonalantibody[30,31]. 2peripheralneuropathy;inadequatehematologic,hepaticorrenalfunction;
Paclitaxel/carboplatinwaschosenascomparatorinthis chronicuseofimmunosuppressiveagentsand/orsystemiccorticosteroids
study,becausethiscombinationisacommonstandardofcare (exceptwhenusedaspremedicationforpaclitaxelinfusionorforthe
fornon-small-celllungcancer(NSCLC)patients,thelargerof managementoftoxiceffect).
thetwocohortsinthistrial[32,33],andalsobecausethe
long-termefficacyofpaclitaxel/carboplatininED-SCLCwas
assessments
comparablewiththatofcisplatin/etoposide,thecommonly
Tumorassessmentsusingradiologicimagingwerecarriedoutatscreening
usedchemotherapycombinationinED-SCLC[3,34,35].
andevery6weeksduringtheinductionphaseandevery12weeksinthe
Sincethetimingofchemotherapyadministrationrelativeto
maintenancephase.AblindedIndependentRadiologicReviewCommittee
immunotherapyhasbeenshowntoaffectoutcome[29,36,37], assessedtumorresponseusingbothmodifiedWorldHealthOrganization
ipilimumabwascombinedwithcarboplatin/paclitaxelusing
(WHO)criteria(mWHO)andnewlyproposedimmune-related(ir)
twoalternateregimens.Intheconcurrentregimen,ipilimumab responsecriteria(irRC)[39,40].TheirRCrepresentsamodificationof
wasadministeredconcurrentlywithpaclitaxel/carboplatin,
mWHOtocapturetheuniquetumorresponsepatternstoipilimumabthat
allowingipilimumabtobepresentattheearliestphaseof includeregressionofindexlesionsinthefaceofnewlesionsandinitial
chemotherapy-inducedantigenrelease.Inthephasedregimen, progression(mWHO)followedbytumorstabilizationordecreaseintumor
paclitaxel/carboplatinalonewasadministeredfollowedby burden[40].Toaccountforthesepatterns,theirRCusedtotaltumor
ipilimumab/paclitaxel/carboplatin,allowingforantigenrelease burdenobtainedbyaddingindexlesionsandmeasurablenewlesionsin
tooccurbeforeipilimumabexposure. determiningtumorresponse;changesinnon-indexornon-measurable
ThestudyenrolledpatientswithED-SCLCaswellasthose lesionswerenotconsidered.irresponsesweredefinedasfollows:ir-
withadvancedNSCLC,andwasdesignedtoanalyzeeach completeresponse(irCR),completedisappearanceofalllesions;ir-partial
cohortseparately.ResultsfortheED-SCLCcohortare response(irPR),≥50%decreaseoftotaltumorburdenfrombaselineir
presentedhere.TheNSCLCcohortisreportedelsewhere[38].
progressivedisease(irPD),≥25%increaseoftotaltumorburdenfrom
nadirandir-stabledisease(irSD),allothersettingsincludingaslowsteady
declineintotaltumorburdenfrombaseline.DetailsoftheirRCare
patients and methods
describedelsewhere[40].ResponsesbybothirRCandmWHOcriteria
wereconfirmedbytwoevaluationsatleast4weeksapart.Assessmentswere
studydesignandtreatment
performeduntilinvestigator-documentedprogressionorunacceptabletoxic
Inthisinternational,randomized,double-blind,multicenterphase2study, effect.Patientswithoutprogressionwhodiscontinuedthetreatmentof
334patientswerestratifiedbydiseasetype(ED-SCLC,n=130;NSCLC, toxiceffectwerefolloweduntiltheyreceivedalternativetherapyor
n=204)andstudysite.Patientsineachstratumwererandomized1:1:1to withdrewconsent.
receiveeitherconcurrent-ipilimumabregimen(fourdosesofipilimumab/ Clinicallaboratoryparameters,AEsandirAEswereassessedateach
paclitaxel(Taxol)/carboplatinfollowedbytwodosesofplacebo/paclitaxel/ dosingcycleandattheendoftreatment.irAEwasdefinedasanAEthat
carboplatin);phased-ipilimumabregimen(twodosesofplacebo/paclitaxel/ wastreatment-relatedandconsistentwithanimmune-mediatedevent.AEs
carboplatinfollowedbyfourdosesofipilimumab/paclitaxel/carboplatin); andirAEsweremonitoredforatleast70daysafterthelastdoseofstudy
orcontrolregimen(uptosixdosesofplacebo/paclitaxel/carboplatin). drugsoruntilanyongoingeventresolvedorstabilized.AEs,irAEsand
Ipilimumab(10mg/kg)orplacebo,paclitaxel(175mg/m2)andcarboplatin laboratoryvaluesweregradedaccordingtotheNationalCancerInstitute
(areaunderthecurve=6)wereadministeredintravenouslyonceevery CommonTerminologyCriteriaforAdverseEvents,version3.0.
3weeksforamaximumof18weeksduringtheinductionphase,starting TheguidelinesforthemanagementofirAEsincludedthe
onday1;thepaclitaxeldosewaschosenbasedonaphase2studyshowing administrationofcorticosteroids(orallyorintravenously),adelayina
thattheresponserateandsurvivalwith175mg/m2didnotdiffer scheduleddose,ordiscontinuationoftherapy.Nodosereductionswere
| Recketal. Volume24| No.1| January2013
Downloaded
from
http://annonc.oxfordjournals.org/
at
St
Petersburg
State
University
on
December
6,
2013
original articles
AnnalsofOncology
allowedforipilimumab.Ipilimumabdosingwasskippedinthecaseof (mWHO-DCR,proportionofpatientswithCR,PRorSDpermWHO)
≥grade2non-dermatologicAEs,≥grade3dermatologicAEsor≥grade andirDCR(proportionofpatientswithirCR,irPRorirSD).
3hematologicabnormalities,untiltheeventimprovedto≤grade1;ifthe Assuming an exponential distribution for irPFS, it was estimated that
eventdidnotimproveto≤grade1,treatmentwasdiscontinued 86 events of 120 randomized ED-SCLC patients among three arms
permanently.Dosemodificationsforpaclitaxelandcarboplatinweremade would provide 74% power to detect a difference in irPFS [hazard ratio
accordingtothepackageinserts/productlabel[41,42].Discontinuationor (HR), 0.6; median for control, 4.5 months] with one-sided α of 0.1.
interruptionofoneagentdidnotprecludecontinuationoftheremainder. Likewise, 57 deaths would provide 57% power to detect a difference in
OS (HR, 0.74; median for control, 10 months). irPFS, mWHO-PFS and
OS were compared between each ipilimumab arm and the control arm
statisticalconsiderations using an unstratified log-rank test with one-sided α of 0.1. No
EfficacyparameterswereanalyzedinallrandomizedpatientsusingSAS multiplicity adjustmentsto α were made. No analysis bystudy sitewas
8.0.Safetyanalysesincludedpatientswhoreceivedatleastonedoseofany conducted. irPFS, mWHO-PFS and OS were estimated using the
studydrug.Primaryendpointforthisstudywasimmune-related Kaplan–Meier product limit method; 95% confidence intervals (CIs) for
progression-freesurvival(irPFS,timefromrandomizationtoirPDor medians were calculated according to Brookmeyer and Crowley [43].
death)intheNSCLCcohort[38].Efficacyendpointsprespecifiedforthe HRs with 95% CIs were estimated for irPFS, mWHO-PFS and OS using
ED-SCLCcohortwereallsecondaryandincludedirPFS,mWHO-PFS(the an unstratified Cox proportional hazards model. irBORR, BORR, irDCR
timefromrandomizationtoPDpermWHO),OS(timefrom and DCR were estimated, and 95% CIs were computed according to
randomizationtodeath),mWHO-bestoverallresponserate(mWHO- Clopperand Pearson [44]. All 95% CIs were two-sided. The patient
BORR,proportionofpatientswithCRorPRpermWHO),irBORR follow-up continued beyond the initial database lock for an updated OS
(proportionofpatientswithirCRorirPR),mWHO-diseasecontrolrate analysis.
Figure1. Adispositionofextensive-disease-small-celllungcancer(ED-SCLC)patientsinStudyCA184-041asof24August2010.Patientswere
randomizedtoeithercontrolregimen(uptosixdosesofplacebo/paclitaxel/carboplatin),concurrent-ipilimumabregimen(fourdosesofipilimumab/
paclitaxel/carboplatinfollowedbytwodosesofplacebo/paclitaxel/carboplatin),orphased-ipilimumabregimen(twodosesofplacebo/paclitaxel/carboplatin
followedbyfourdosesofipilimumab/paclitaxel/carboplatin).Patientswhodiscontinuedtreatmentmayhavedifferentiallydiscontinuedoneormorestudy
therapyandmayhavereceivedpaclitaxeland/orcarboplatinassubsequenttherapy.‘Completedinductionphase’indicatesthatapatientcompleted
inductionphasewithoutenteringmaintenancephase.Thedispositionofnon-small-celllungcancer(NSCLC)patientsinthisstudycanbefound(Lynch
etal.[38].
Volume24| No.1 |January2013 doi:10.1093/annonc/mds213 | 
Downloaded
from
http://annonc.oxfordjournals.org/
at
St
Petersburg
State
University
on
December
6,
2013
original articles
AnnalsofOncology
results phased-ipilimumabarm,31%),andpatientswithelevated
lactatedehydrogenaselevels(control,42%;concurrent
patientdispositionandcharacteristics
ipilimumab,58%;phasedipilimumab,48%).
Onehundredandthirtypatientswithpreviouslyuntreated
ED-SCLCwererandomizedbetweenJune2008andAugust treatmentexposure
2009in32centersacrosssevencountries,andallbuttwo
Themediannumberofipilimumabdosesadministeredover
patients(reasonsnotreported)weretreated(Figure1).The
theentiretreatmentperiod(inductionplusmaintenance)was
initialdatabaselocktookplaceon27August2010witha fourinboththeconcurrent-ipilimumab(range,1–12doses)
minimumfollow-upof11.1months.Atthislock,allpatients, andphased-ipilimumab(1–7doses)arms.Eachipilimumab-
exceptfortwointheconcurrent-ipilimumabandoneinthe containingarmhad12patients(29%)receivingfiveormore
controlarms,wereofftreatment.Themainreasonfor
dosesofipilimumab.Themediannumberofpaclitaxeldoses
treatmentdiscontinuationwasdiseaseprogression.Asshown administeredwasfiveintheconcurrent-ipilimumab(range,1–
insupplementaryTableS1,availableatAnnalsofOncology 6)andsixinboththephased-ipilimumab(range,2–6)and
online,baselinedemographicsanddiseasecharacteristicswere control(range,1–6)arms.Themediannumberofcarboplatin
generallybalancedacrossarms,exceptforpatientsagedover dosesgivenwassixinboththecontrol(range,1–6)and
65years(control,20%;concurrent-ipilimumabarm,19%; phased-ipilimumab(range,2–6)arms,andfiveinthe
Figure2. Kaplan–Meierplotsforprogression-freesurvival(PFS)perimmune-related(ir)responsecriteria(irPFS).Toaccountfortheuniquetumor
responsepatternstoipilimumab,immune-relatedresponsecriteria(irRC)wasproposed.PerirRC,newlesions,whethermeasurableornot,werenot
consideredprogression.Measurablenewlesionswereratheraddedtotheindexlesionstoobtaintotaltumorburden,anda≥25%reductioninthistotal
tumorburdenfromnadirwasdefinedasimmune-relatedprogression.irPFSwasdefinedasthetimefromtherandomizationtoimmune-relatedprogression
[asdeterminedbyanIndependentRadiologicReviewCommittee(IRRC)]ordeath.Asindicatedbysymbols,patientswhoneitherprogressednordiedwere
censoredonthedateoflasttumorassessment.P-valuesarebasedonanunstratifiedlog-ranktestwithaone-sidedαof0.1.
| Recketal. Volume24| No.1| January2013
Downloaded
from
http://annonc.oxfordjournals.org/
at
St
Petersburg
State
University
on
December
6,
2013
original articles
AnnalsofOncology
concurrent-ipilimumabarm(range,1–6).Thenumberof themediansbeing5.2monthsforcontrol,5.2monthsfor
patientsenteringthemaintenancephasewas14(32%)inthe phasedipilimumaband3.9monthsforconcurrentipilimumab
control,12(29%)intheconcurrent-ipilimumaband15(36%) (Figure3).
inthephased-ipilimumabarms.Themediannumberof Attheinitialanalysis(datacut-off;27August2010)with99
ipilimumabdosesreceivedinthemaintenancephasewas1.5 deaths(76%)reported,medianOSforphasedipilimumabwas
(range,1–8)forconcurrent-ipilimumaband1(range,1–3)for 12.9months,anincreaseof3.0monthsoverthemedianof9.9
phased-ipilimumabarms,withthemediannumberofplacebo monthsforcontrol(HR,0.75;P=0.13;Figure4).MedianOS
inthecontrolarmbeing1(range,1–5). forconcurrentipilimumabwas9.1months.Inafollow-upOS
analysiswith114deaths(88%)reported(datacut-off:5
efficacy January2011),medianOSwas10.5months(95%CI,8.6–11.7)
forcontrol,12.5months(95%CI,7.9–14.9)forphased
ProgressionwasassessedusingboththeirRCcriteria(see
PatientsandMethods)andmodifiedWHOcriteria.The ipilimumaband 9.1months(95%CI,6.7–13.0)forconcurrent
ipilimumab.TheHRvaluesrelativetocontrolwere0.76(95%
phased-ipilimumabregimenimprovedirPFScomparedwith
CI,0.48–1.19)forphasedipilimumaband0.89(95%CI,0.57–
control(HR,0.64;P=0.03,Figure2),whiletheconcurrent-
1.39)forconcurrentipilimumab.
ipilimumabregimendidnot (HR,0.75;P=0.11).Median
Tumorresponseratesappearedtofavorphasedipilimumab,
irPFSwas5.3monthsforcontrol,6.4monthsforphased-
butnotconcurrentipilimumab,overcontrol,thedifferences
ipilimumaband5.7monthsforconcurrent-ipilimumab
beinggreaterwhenassessedbyirRC(Table1).irBORRwas
regimens(Figure2).mWHO-PFSwassimilaracrossarmswith
Figure3. Kaplan–Meierplotsforprogression-freesurvivalpermodifiedWHOcriteria(mWHO-PFS).PermWHO,areductioninindexlesionsby≥25%,
anynewlesions(measurableornot)orprogressionofnon-indexlesionswereconsideredanmWHOprogression.mWHO-PFSwasdefinedasthetime
fromtherandomizationtomWHOprogression(asdeterminedbyanIRRC)ordeath.Asindicatedbysymbols,patientswhoneitherprogressednordied
werecensoredonthedateoflasttumorassessment.P-valuesarebasedonanunstratifiedlog-ranktestwithaone-sidedαof0.1.
Volume24| No.1 |January2013 doi:10.1093/annonc/mds213 | 
Downloaded
from
http://annonc.oxfordjournals.org/
at
St
Petersburg
State
University
on
December
6,
2013
original articles
AnnalsofOncology
Figure4. Kaplan–Meierplotsforoverallsurvival(OS).OSwasdefinedasthetimefromrandomizationuntildeathfromanycause.Asindicatedby
symbols,patientswhohadnotdiedorwhowerelosttothefollow-upwerecensoredonthelastdateonwhichtheywereknowntohavebeenalive.Data
cut-offforthisanalysiswas27August2010.P-valuesarebasedonanunstratifiedlog-ranktestwithaone-sidedαof0.1.
Table1. Tumorresponseanddiseasecontrol
Response Control(n=45) Concurrentipilimumab(n=43) Phasedipilimumab(n=42)
ir-BOR,n(%)
irCR 0 1(2) 0
irPR 24(53) 20(47) 30(71)
irSD 19(42) 14(33) 9(21)
irPD 0 0 2(5)
Unknown 2(4) 8(19) 1(2)
irBORR,%(95%CI) 53(38,68) 49(33,65) 71(55,84)
irDCR,%(95%CI) 96(85,100) 81(67,92) 93(81,99)
mWHO-BOR,n(%)
CR 0 1(2) 0
PR 22(49) 13(30) 24(57)
SD 20(44) 16(37) 10(24)
PD 0 5(12) 8(19)
Unknown 3(7) 8(19) 0
mWHO-BORR,%(95%CI) 49(34,64) 33(19,49) 57(41,72)
mWHO-DCR,%(95%CI) 93(82,99) 70(54,83) 81(66,91)
ir,immunerelated;BOR,bestoverallresponse;CR,completeresponse;PR,partialresponse;SD,stabledisease,PD,progressivedisease;BORR,bestoverall
responserate;DCR,diseasecontrolrate;mWHO,modifiedWHO;CI,confidenceinterval.
| Recketal. Volume24| No.1| January2013
Downloaded
from
http://annonc.oxfordjournals.org/
at
St
Petersburg
State
University
on
December
6,
2013
original articles
AnnalsofOncology
Table2. Adverseeventsandlaboratoryabnormalities
Events,% Control(n=44) Concurrentipilimumab(n=42) Phasedipilimumab(n=42)
Grade1/2 Grade3 Grade4 Grade1/2 Grade3 Grade4 Grade1/2 Grade3 Grade4
Anyadverseevent 39 34 9 24 38 7 26 36 17
Anytreatment-relatedadverseevent 61 23 7 41 36 7 45 36 14
Treatment-relatednon-hematologicadverseevents
Fatigue 20 5 0 24 7 0 17 12 0
Alopecia 59 n/a n/a 57 n/a n/a 67 n/a n/a
Rash 2 0 0 31 5 0 24 0 0
Pruritus 5 0 0 24 0 0 17 2 0
Arthralgia 32 0 0 24 0 0 36 10 0
Decreasedappetite 9 0 0 17 2 0 10 0 0
Diarrhea 11 5 0 21 2 2 24 10 0
Nausea 20 2 0 24 0 0 29 0 0
Peripheralneuropathy 11 0 0 14 0 0 24 0 0
Peripheralsensoryneuropathya 32 0 0 24 0 0 33 0 0
Hematologicabnormalitiesb
Thrombocytopenia 61 2 0 44 3 0 50 5 2
Neutropenia 40 2 0 41 5 3 40 5 5
Anemia 84 7 0 87 5 0 81 5 5
Liverfunctionenzymesb
ALT 21 0 0 36 15 3 36 2 2
AST 33 0 0 39 10 3 33 7 0
Adverseeventslistedwerethose(anygrade)reportedinatleast15%oftreatedpatientsinanyarm.Patientscouldhavemorethanoneadverseevent.
aAsreportedbyinvestigators(standardizedMedDRAquerytermscope).
bBasedonlaboratoryresults;n/a,notapplicable;ALT,alanineaminotransferase;AST,aspartateaminotransferase.
53%forcontrol,49%forconcurrentipilimumab(including ipilimumab.Therewerenograde4eventsofrashorpruritus.
oneirCR)and71%forphasedipilimumab;corresponding Alleventsofseverediarrheaweregrade3,exceptforonegrade
mWHO-BORRswere49,33(includingoneCR)and57%, 4eventforconcurrentipilimumab.Oneoccurrenceofgrade3
respectively(Table1).irDCRsforcontrol,concurrent- colitiswasrecordedforphasedipilimumab.Therewerefour
ipilimumabandphased-ipilimumabregimenswere96,81and casesofgrade3arthralgiaforphasedipilimumab.Grade3/4
93%,respectively.CorrespondingmWHO-DCRswere93,70 increasesinalanineaminotransferasewerenotedinseven
and81%,respectively.Inthecontrolarm,responseratesby patients(grade3six,grade4one)forconcurrentipilimumab,
irRCweresimilartothosebymWHOcriteria. twopatients(grade3one,grade4one)forphasedipilimumab
andnoneforcontrol.Thecorrespondingvaluesforaspartate
safety
aminotransferasewerefivepatients(grade3four,grade4one),
threepatients(allgrade3)andnone,respectively.Therewere
AsshowninTable2,theoverallincidenceoftreatment-related
twocasesofgrade4hepatitis,one(2%)ineachipilimumab-
grade3/4AEsappearedmorecommoninipilimumab-
containingarm.Therewasnooccurrenceofhypophysitis,
containingarms(concurrent,43%;phased,50%)thaninthe
althoughonegrade3eventofdecreasedvisualacuitywas
controlarm(30%).However,ratesofAE-related
reportedforphasedipilimumab.Onedeathintheconcurrent-
discontinuationweresimilaracrossarms(control,9%;
ipilimumabarmwasattributedtotreatment-related
concurrent,7%;phased,5%;Figure1).
Someofthemostcommonnon-hematologicAEs(≥15%, hepatotoxicity.
anygrade),includingfatigue,alopecia,nauseaandperipheral
sensoryneuropathy,weregenerallysimilaracrossarmsin
discussion
termsoffrequencyandseverity.TheothercommonAEs
includingrash,pruritusanddiarrheaoccurredmorefrequently ThisfirststudyofipilimumabinpatientswithED-SCLC
intheipilimumab-containingarmscomparedwithcontrol, showedthatthephased-ipilimumabregimenprolongedOS
andtheseAEswerealsoidentifiedasirAEsperprotocol- numericallycomparedwithpaclitaxel/carboplatinalone
definedcriteria.AsshowninTable2,hematologic (median,12.9versus9.9months;HR,0.75;P=0.13).There
abnormalities(anygrades)weregenerallysimilaracrossarms, wasimprovementinirPFS(HR,0.64;P=0.03)butnotin
althoughgrade3/4abnormalitiesappearedmorefrequentin mWHO-PFS(HR,0.93;P=0.37).Theresponsedatabasedon
theipilimumab-containingarmsversuscontrol(7–10%versus thenewlyproposedirRCcriteria,whichhaveyettobe
2%). validated,donotallowfirmconclusionsandmustbe
Theoverallincidenceofgrade3/4irAEswas9%forcontrol, consideredhypothesisgenerating.Retrospectiveanalysisof
21%forconcurrentipilimumaband17%forphased datafromphase2studiesinpatientswithmetastatic
Volume24| No.1 |January2013 doi:10.1093/annonc/mds213 | 
Downloaded
from
http://annonc.oxfordjournals.org/
at
St
Petersburg
State
University
on
December
6,
2013
original articles
AnnalsofOncology
melanomasuggeststhattheirRCmaybettercapturethe study[38].Ipilimumabdidnotappeartoexacerbatetoxic
activityofipilimumabthantheWHOcriteria[18,40,45].Two effectsobservedwithpaclitaxel/carboplatinalone,andthe
ongoingphase3trialsofipilimumabinlungcancer profileofirAEswasconsistentwithpreviousexperiencefrom
(ClinicalTrials.govidentifiers:NCT01285609and otheripilimumabstudies.Aphase3trial(NCT01450761)
NCT01450761)willevaluateprospectivelyifirPFSmaybetter comparingphasedipilimumabplusetoposide/platinum
correlatewithOSthanmWHO-PFS. therapywithetoposide/platinumtherapyaloneinpatientswith
Noimprovementsinefficacyendpointsstudiedincluding newlydiagnosedED-SCLCisunderway.
irPFS,mWHO-PFS,OSandtumorresponsewerenotedwith
concurrentipilimumab.Whilefactorscontributingtothe
acknowledgements
activityseenwithphasedipilimumabareunknown,itis
interestingtospeculatethattheexposuretochemotherapy Contributionsofpatientsandinvestigatorswhoparticipatedin
beforeipilimumabmayhavecontributedtotheenhancement thesestudiesaregratefullyacknowledged.Writing,editorial
ofantitumorimmuneresponsebyipilimumab.Studiesin andadministrativeassistancewasprovidedbyMotasimBillah,
preclinicaltumormodelsandinpatientssuggestthat anemployeeofBristol-MyersSquibb.
sequencingofchemotherapyandimmunotherapymayaffect
clinicaloutcome[36,37,46].
funding
ThecommonAEsseenduringthestudythataretypically
associatedwithpaclitaxel/carboplatin,includingalopecia,
ThestudywassponsoredbyBristol-MyersSquibb.
fatigue,nauseaandperipheralneuropathy,weregenerally
unaffectedbytheadditionofipilimumab.Consistentwith
previousexperiencefromotherstudies[20,21],themost disclosures
commonirAEsinvolvedskin(rashandpruritus)and
DrMartinReckhasreceivedhonorariafromAstraZeneca,
gastrointestinaltract (diarrhea),andoccurredmorefrequently
Daiichi,MerckandRocheandwasontheadvisoryboardsof
intheipilimumab-containingarms.Treatment-relatedAEs,
AstraZeneca,Bristol-MyersSquibb,Daiichi,Lilly,Pfizerand
irAEsandlaboratoryabnormalitiesweremostlygrade1/2.
Roche.DrThomasLynchholdsstockofInfinity
Overallratesoftreatment-relatedgrade3/4AEsappeared
Pharmaceuticals,receivesroyaltiesfromPartnersHealthcare
higherforipilimumab-containingregimenscomparedwiththe
andhasreceivedhonorariafromAstex,BoehringerIngelheim,
control,asweretheoccurrenceofalanineaminotransferase
InfinityPharmaceuticalsandMerck.Allotherauthorshave
andaspartateaminotransferaseelevations.Mostgrade3/4
irAEsweremanagedbytheprotocol-specifiedtreatment
declarednoconflictofinterest.
guidelinesincludingclosepatientfollow-upandtheearly
administrationofsystemiccorticosteroids[21,47].Overall,in references
thisphase2trial,thecombinationofipilimumabplus
paclitaxel/carboplatinexhibitedanacceptablesafetyprofilein 1. PuglisiM,DollyS,FariaAetal.Treatmentoptionsforsmallcelllungcancer–do
wehavemorechoice?BrJCancer2010;102:629–638.
ED-SCLCpatients.
2. ArgirisA,MurrenJR.Stagingandclinicalprognosticfactorsforsmall-celllung
Amajorlimitationofthisanalysisissmallstudypopulation,
cancer.CancerJ2001;7:437–447.
althoughgiventherelativerarityofED-SCLC,thepopulation
3. OzeI,HottaK,KiuraKetal.Twenty-sevenyearsofphaseIIItrialsforpatients
(n=130)studiedhereisalargeseries.ThefactthatirRChas
withextensivediseasesmall-celllungcancer:disappointingresults.PLoSOne
notyetbeenvalidatedwarrantscautionininterpretingthe 2009;4:e7835.
irRC-baseddatadescribedhere.WhileirRCappearedtohave 4. WalunasTL,LenschowDJ,BakkerCYetal.CTLA-4canfunctionasanegative
capturedtheuniquepatternsofipilimumab’stumorresponse regulatorofTcellactivation.Immunity1994;1:405–413.
inthispatientcohort,only8ofthe28patientswhohadPD 5. KrummelMF,AllisonJP.CD28andCTLA-4haveopposingeffectsonthe
(mWHO)withoutirPDwerefolloweduntilirPD,precludinga
responseofTcellstostimulation.JExpMed1995;182:459–465.
fullassessmentofimmune-relatedresponses.Anadditional 6. LeachDR,KrummelMF,AllisonJP.EnhancementofantitumorimmunitybyCTLA-
4blockade.Science1996;271:1734–1736.
limitationistheuseofpaclitaxel(Bristol-MyersSquibb,
7. PageDB,YuanJ,WolchokJD.TargetingcytotoxicT-lymphocyteantigen4in
Princeton,NewJersey)/carboplatinascomparator,because
immunotherapiesformelanomaandothercancers.Immunotherapy2010;2:
combinationsofcisplatin(Bristol-MyersSquibb,Princeton, 367–379.
NewJersey)orcarboplatin(Bristol-MyersSquibb,Princeton,
8. HoosA,IbrahimR,KormanAetal.Developmentofipilimumab:contributiontoa
NewJersey)withetoposide(GensiaSicorPharmaceuticals, newparadigmforcancerimmunotherapy.SeminOncol2010;37:533–546.
Inc.,Irvine,California)arethemostcommonlyusedstandard 9. TarhiniA,LoE,MinorDR.Releasingthebrakeontheimmunesystem:ipilimumab
ofcareforSCLC.While,atthetimethisstudywasdesigned, inmelanomaandothertumors.CancerBiotherRadiopharm2010;25:601–613.
preclinicaldatawereavailableonlyforthecombinationof 10. AttiaP,PhanGQ,MakerAVetal.Autoimmunitycorrelateswithtumorregression
ipilimumabandpaclitaxel,subsequentpreclinicalstudies inpatientswithmetastaticmelanomatreatedwithanti-cytotoxicT-lymphocyte
antigen-4.JClinOncol2005;23:6043–6053.
showedsynergybetweenetoposideandipilimumab[30].
11. MakerAV,PhanGQ,AttiaPetal.Tumorregressionandautoimmunityinpatients
Inconclusion,ipilimumabincombinationwithpaclitaxel/
treatedwithcytotoxicTlymphocyte-associatedantigen4blockadeand
carboplatinappearedtoshowclinicalactivityinpatientswith interleukin2:aphaseI/IIstudy.AnnSurgOncol2005;12:1005–1016.
previouslyuntreatedED-SCLCwhenadministeredasphased
12. YangJC,HughesM,KammulaUetal.Ipilimumab(anti-CTLA4antibody)causes
butnotasconcurrentregimen.Clinicalactivitywiththe regressionofmetastaticrenalcellcancerassociatedwithenteritisand
phasedregimenwasalsoreportedintheNSCLCcohortofthis hypophysitis.JImmunother2007;30:825–830.
| Recketal. Volume24| No.1| January2013
Downloaded
from
http://annonc.oxfordjournals.org/
at
St
Petersburg
State
University
on
December
6, 2013
original articles
AnnalsofOncology
13. KleinO,EbertLM,NicholaouTetal.Melan-A-specificcytotoxicTcellsare 32. Kosmidis P, MylonakisN, SkarlosD et al. Paclitaxel(175 mg/m2) plus
associatedwithtumorregressionandautoimmunityfollowingtreatmentwithanti- carboplatin (6AUC) versuspaclitaxel (225mg/m2) pluscarboplatin (6 AUC) in
CTLA-4.ClinCancerRes2009;15:2507–2513. advancednon-small-cell lung cancer (NSCLC):a multicenter randomizedtrial.
14. HodiFS,DranoffG.Thebiologicimportanceoftumor-infiltratinglymphocytes. HellenicCooperative OncologyGroup (HeCOG). Ann Oncol2000;11:
JCutanPathol2010;37(Suppl1):48–53. 799–805.
15. SmallEJ,TchekmedyianNS,RiniBIetal.ApilottrialofCTLA-4blockadewith 33. SchillerJH,HarringtonD,BelaniCPetal.Comparisonoffourchemotherapy
humananti-CTLA-4inpatientswithhormone-refractoryprostatecancer.Clin regimensforadvancednon-small-celllungcancer.NEnglJMed2002;346:
CancerRes2007;13:1810–1815. 92–98.
16. AnsellSM,HurvitzSA,KoenigPAetal.PhaseIstudyofipilimumab,ananti- 34. GridelliC,ManzioneL,PerroneFetal.Carboplatinpluspaclitaxelinextensive
CTLA-4monoclonalantibody,inpatientswithrelapsedandrefractoryB-cellnon- smallcelllungcancer:amulticentrephase2study.BrJCancer2001;84:
Hodgkinlymphoma.ClinCancerRes2009;15:6446–6453. 38–41.
17. HodiFS,ButlerM,ObleDAetal.Immunologicandclinicaleffectsofantibody 35. ThomasP,CastelnauO,PaillotinDetal.PhaseIItrialofpaclitaxeland
blockadeofcytotoxicTlymphocyte-associatedantigen4inpreviouslyvaccinated carboplatininmetastaticsmall-celllungcancer:aGroupeFrancaisdePneumo-
cancerpatients.ProcNatlAcadSciUSA2008;105:3005–3010. Cancerologiestudy.JClinOncol2001;19:1320–1325.
18. O’DaySJ,MaioM,Chiarion-SileniVetal.Efficacyandsafetyofipilimumab 36. Nowak AK, Lake RA, Marzo AL et al. Induction of tumor cell apoptosis in
monotherapyinpatientswithpretreatedadvancedmelanoma:amulticenter vivo increases tumorantigen cross-presentation, cross-priming rather than
single-armphaseIIstudy.AnnOncol2010;21:1712–1717. cross-tolerizing host tumor-specific CD8 T cells. J Immunol 2003; 170:
19. HodiFS,O’DaySJ,McDermottDFetal.Improvedsurvivalwithipilimumabin 4905–4913.
patientswithmetastaticmelanoma.NEnglJMed2010;363:711–723. 37. AntoniaSJ,MirzaN,FrickeIetal.Combinationofp53cancervaccinewith
20. RobertC,ThomasL,BondarenkoIetal.Ipilimumabplusdacarbazineforpreviously chemotherapyinpatientswithextensivestagesmallcelllungcancer.Clin
untreatedmetastaticmelanoma.NEnglJMed2011;364:2517–2526. CancerRes2006;12:878–887.
21. MaddisonP,Newsom-DavisJ,MillsKRetal.FavourableprognosisinLambert- 38. LynchT,BondarenkoI,LuftAetal.Ipilimumabincombinationwithpaclitaxel
Eatonmyasthenicsyndromeandsmall-celllungcarcinoma.Lancet1999;353: andcarboplatinasfirst-linetreatmentinstageIIIB/IVnon-small-celllungcancer:
117–118. resultsfromarandomized,double-blind,multi-centerphase2study.JClin
Oncol2012;30:2046–2054.
22. TaniT,TanakaK,IdezukaJetal.RegulatoryTcellsinpraneoplasticneurological
syndromes.JNeuroimmunol2008;196:166–169. 39. MillerAB,HoogstratenB,StaquetMetal.Reportingresultsofcancertreatment.
Cancer1981;47:207–214.
23. MerrittRE,MahtabifardA,YamadaREetal.CisplatinaugmentscytotoxicT-
lymphocyte-mediatedantitumorimmunityinpoorlyimmunogenicmurinelung 40. WolchokJD,HoosA,O’DaySetal.Guidelinesfortheevaluationofimmune
cancer.JThoracCardiovascSurg2003;126:1609–1617. therapyactivityinsolidtumors:immune-relatedresponsecriteria.ClinCancer
Res2009;15:7412–7420.
24. TesniereA,ApetohL,GhiringhelliFetal.Immunogeniccancercelldeath:akey-
lockparadigm.CurrOpinImmunol2008;20:504–511. 41. Taxol(paclitaxel).USFullPrescribingInformation.Princeton,NJ:Bristol-Myers
Squibb2010.
25. ApetohL,TesniereA,GhiringhelliFetal.Molecularinteractionsbetweendying
tumorcellsandtheinnateimmunesystemdeterminetheefficacyofconventional 42. Paraplatin(carboplatin).USFullPrescribingInformation.Princeton,NJ:Bristol-
anticancertherapies.CancerRes2008;68:4026–4030. MyersSquibb2008.
26. CorrealeP,DelVecchioMT,LaPlacaMetal.Chemotherapeuticdrugsmaybe 43. BrookmeyerR,CrowleyJ.Aconfidenceintervalforthemediansurvivaltime.
usedtoenhancethekillingefficacyofhumantumorantigenpeptide-specific Biometrics1982;38:29–41.
CTLs.JImmunother2008;31:132–147. 44. ClopperC,PearsonE.Theuseofconfidenceorfiduciallimitsillustratedinthe
27. RamakrishnanR,AssudaniD,NagarajSetal.Chemotherapyenhancestumor
caseofthebinomial.Biometrika1934;26:404–413.
cellsusceptibilitytoCTL-mediatedkillingduringcancerimmunotherapyinmice. 45. Wolchok JD, Neyns B, Linette G et al. Ipilimumab monotherapy in patients
JClinInvest2010;120:1111–1124. with pretreated advanced melanoma: a randomised, double-blind,
28. EmensLA.Chemoimmunotherapy.CancerJ2010;16:295–303. multicentre, phase 2, dose-ranging study. Lancet Oncol 2010; 11:
155–164.
29. ZitvogelL,ApetohL,GhiringhelliFetal.Immunologicalaspectsofcancer
chemotherapy.NatRevImmunol2008;8:59–73. 46. BralyP,NicodemusCF,ChuCetal.Theimmuneadjuvantpropertiesoffront-line
carboplatin-paclitaxel:arandomizedphase2studyofalternativeschedulesof 30. MastersG,BarretoL,GiritEetal.AntitumoractivityofcytotoxicT-lymphocyte
intravenousoregovomabchemoimmunotherapyinadvancedovariancancer. antigen-4blockadealoneorcombinedwithpaclitaxel,etoposideorgemcitabine
JImmunother2009;32:54–65.
inmurinemodels.JImmunother2009;32:994(Abstract).
47. Di Giacomo AM, Biagioli M, Maio M. The emerging toxicity profiles of anti-
31. LeeF,Jure-KunkelMN,SalvatiME.Synergisticactivityofixabepiloneplusother
CTLA-4 antibodies across clinical indications. Semin Oncol 2010; 37:
anticanceragents:preclinicalandclinicalevidence.TherAdvMedOncol2011;
3:11–25.
499–507.
Volume24| No.1 |January2013 doi:10.1093/annonc/mds213 | 
Downloaded
from
http://annonc.oxfordjournals.org/
at
St
Petersburg
State
University
on
December
6,
2013
